Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma

World Journal of Gastroenterology

Volumn 12, Issue 40, 2006, Pages 6531-6535

  Tomizawa, Minoru ^a   Saisho, Hiromitsu ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

3 (4, 5 dimethylthiazol 2 yl) 5 (3 carbo xymethoxyphenyl) 2 (4 sulfophenyl) 2H tetrazolium inner salt assay; Hepatoblastoma; Mitogen activated protein kinase; Molecular therapy; Phospatidyl inositol 3 kinase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; EOSIN; HEMATOXYLIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG TARGETING; HEPATOBLASTOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING;

EID: 33751001327     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i40.6531     Document Type: Article

References (12)

1. Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. Cancer 1967; 20: 396-422
2. Brown AL, Graham DE, Nissley SP, Hill DJ, Strain AJ, Rechler MM. Developmental regulation of insulin-like growth factor II mRNA in different rat tissues. J Biol Chem 1986; 261: 13144-13150
3. Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH, Meng XY. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol 2005; 11: 4655-4660
4. Poirier K, Chalas C, Tissier F, Couvert P, Mallet V, Carrie A, Marchio A, Sarli D, Gicquel C, Chaussade S, Beljord C, Chelly J, Kerjean A, Terris B. Loss of parental-specific methylation at the IGF2 locus in human hepatocellular carcinoma. J Pathol 2003; 201: 473-479
5. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-137
6. Lund P, Schubert D, Niketeghad F, Schirmacher P. Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett 2004; 206: 85-96
7. Hopfner M, Huether A, Suffer AP, Baradari V, Schuppan D, Scherubl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 2006; 71: 1435-1448
8. Gray SG, Eriksson T, Ekstrom C, Holm S, von Schweinitz D, Kogner P, Sandstedt B, Pietsch T, Ekstrom TJ. Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer 2000; 82: 1561-1567
9. Tokiwa T, Doi I, Sato J. Preparation of single cell suspensions from hepatoma cells in culture. Acta Med Okayama 1975; 29: 147-150
10. Lin SB, Hsieh SH, Hsu HL, Lai MY, Kan LS, Au LC. Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II. J Biochem (Tokyo) 1997; 122: 717-722
11. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 2004; 23: 7854-7862
12. Mitsui H, Takuwa N, Maruyama T, Maekawa H, Hirayama M, Sawatari T, Hashimoto N, Takuwa Y, Kimura S. The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int J Cancer 2001; 92: 55-62